Background Rivaroxaban is a first-line option for the management of venous
thromboembolism (VTE). However, limited data are available regarding its effectiveness in …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Obesity is an epidemic with rising prevalence, and obese patients are predisposed to
comorbid conditions that increase risk for thromboembolic events. It is critical to identify safe …

Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …

Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Prior observational studies suggest rivaroxaban is safe and effective among patients with
morbid obesity who suffered a venous thromboembolism (VTE) event, but existing data are …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …

Abstract Background The International Society on Thrombosis and Haemostasis
recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body …

Background: Studies of acute venous thromboembolism (VTE) and non-valvular atrial
fibrillation (AF) have shown comparable therapeutic efficacy and similar or lower bleeding …

There are currently more than 7 million patients taking a direct oral anticoagulant (DOAC),
with more new prescriptions per year than warfarin. Despite impressive efficacy and safety …